Johnson & Johnson Has No Plans to Enter Obesity Drugs Market
Johnson & Johnson CEO Joaquin Duato stated in an interview that the company has no plans to enter the booming obesity drug market, choosing instead to focus on diseases like cancer. This sets J&J apart from many rivals seeking to develop obesity medicines.
Johnson & Johnson (JNJ) CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations that the company has no plans to enter the booming obesity market. Instead, it will focus on diseases such as cancer.
Details of the Stance
Duato's comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. (LLY) and Novo Nordisk.
Context
The obesity drug market is experiencing a boom, with estimates valuing it at tens of billions of dollars. However, Johnson & Johnson believes that focusing on other therapeutic areas such as oncology and immunology is the better strategic choice.
What It Means for Investors
Johnson & Johnson's decision to stay out of the obesity drug market reflects a clear strategy to concentrate on its core areas. Some investors may view this as missing a significant growth opportunity, while others may see it as prudent to avoid intense competition in this space.
Frequently Asked Questions
Found this useful? Share it